Shelley R. Salpeter, MD; Thomas M. Ormiston, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Salpeter SR, Ormiston TM. Use of β-Blockers in Patients with Reactive Airway Disease. Ann Intern Med. 2003;139:304. doi: 10.7326/0003-4819-139-4-200308190-00021
Download citation file:
Published: Ann Intern Med. 2003;139(4):304.
We agree that further study of the long-term effects of β-blockers in patients with reactive airway disease is needed. Our study demonstrated the safety of cardioselective β-blockers in patients with mild to moderate reactive airway disease who were followed for up to 4 weeks. We believe that this study paves the way for larger, long-term trials to be done. In the meta-analysis, patients who received a single dose or continued treatment with a cardioselective β-blocker had an increased FEV1 response to β-agonists compared with placebo. Furthermore, in the continued treatment trials, steroid use, asthma exacerbations, and hospitalizations did not increase.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only